Lieske JC, Milliner DS, Beara-Lasic L, Harris P, Cogal A, Abrash E.
2012 Aug 9 [updated 2017 Dec 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
PMID:22876375
Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.
Namba N, Kubota T, Muroya K, Tanaka H, Kanematsu M, Kojima M, Orihara S, Kanda H, Seino Y, Ozono K.
J Endocr Soc. 2022 Feb 11;6(5):bvac021. doi: 10.1210/jendso/bvac021. eCollection 2022 May 1.
PMID:35356008
A Rare Presentation of Rickets Mimicking Sacroiliitis: A Case Report and Literature Review.
Ali RS, Abdulhussein R, Esrick M, Sen M.
Cureus. 2022 Jun 17;14(6):e26033. doi: 10.7759/cureus.26033. eCollection 2022 Jun.
PMID:35865447
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M.
Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.
Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M.
Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia.
Zhang X, Peyret T, Gosselin NH, Marier JF, Imel EA, Carpenter TO.
Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications?
Gerin M, Jambon G, Fouque-Aubert A, Raybaud C, Cochat P, Claris O, Bacchetta J.